AITOPAI热报
USGuidelineConsultationHealthModel providers

FDA framework for generative AI in medical devices (comment stage)

FDA 医疗器械生成式 AI 监管框架（征求意见阶段）
FDA·Published 2026-11-03·Checked by 管理员 on 2026-11-10

The U.S. Food and Drug Administration held a public comment process on how it should regulate generative AI in medical devices, covering approval pathways and ongoing oversight. Hundreds of comments were submitted by patients, providers, and medtech companies, and the feedback will shape the eventual regulatory framework.

Source ↗Remind meUS · All

What it means for you

  • Following the comment period, FDA will develop a regulatory framework for generative AI medical devices, and approval and post-market oversight requirements will change existing submission pathways.
  • Companies selling medical devices with generative AI features in the US must track the final framework and prepare evidence systems that meet ongoing oversight requirements.
  • Companies that submitted comments have already had the opportunity to influence the rules and reduce future compliance costs.

    • What to do

    ComplianceTrack FDA's forthcoming generative AI medical device framework and assess its impact
    LegalInventory generative AI features in current products and identify approval and post-market oversight evidence gaps
    EngineeringBuild change-management and continuous performance monitoring for generative AI models to prepare for future requirements

    Key dates

    2026-11-03Published

    Source documents

    Source ↗

    Coverage

    Stories in the feed
    Editorial summary, not legal advice; dates and status follow the original document. · Report a correction